ARCHIVES

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Extends PRI’s Fredrick Contract Six Months

September 23, 1994

Particle Therapy Program Would cost $600 million Over 10 Years for 16 Facilities, Clinical Trials

December 2, 1977

Obituaries: Keith Amos, Trudy Small, and Kie Kian Ang

June 21, 2013

“Imaginary Treatments,” “Wonderful Cures”

June 6, 1997

NCI to Close Clinical Branch at Frederick, Move Patients, Protocols To Bethesda

May 17, 1996

Tough Year Seen for Cooperative Groups; Priority Payment Questioned

December 2, 1988